These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 14652655

  • 1. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
    Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Haemost; 2003 Dec; 90(6):1187-91. PubMed ID: 14652655
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
    Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM.
    Circulation; 1999 Oct 12; 100(15):1616-22. PubMed ID: 10517732
    [Abstract] [Full Text] [Related]

  • 4. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting.
    Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, Seidelin PH, Natarajan MK, Cohen EA, Strauss BH.
    Eur Heart J; 2004 Jun 12; 25(12):1029-35. PubMed ID: 15191773
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
    Christ G, Nikfardjam M, Huber-Beckmann R, Gottsauner-Wolf M, Glogar D, Binder BR, Wojta J, Huber K.
    J Thromb Haemost; 2005 Feb 12; 3(2):233-9. PubMed ID: 15670026
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Feb 12; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 9. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI).
    Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group.
    Thromb Haemost; 2003 Mar 12; 89(3):554-60. PubMed ID: 12624641
    [Abstract] [Full Text] [Related]

  • 10. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 12; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 11. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 May 12; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients.
    Gottsauner-Wolf M, Sochor H, Hornykewycz S, Beckmann R, Lang I, Probst P, Binder BR, Huber K.
    Thromb Haemost; 1999 Apr 12; 81(4):522-6. PubMed ID: 10235432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 12; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
    Wexberg P, Jordanova N, Strehblow C, Syeda B, Meyer B, Charvat S, Zorn G, Scheinig D, Wojta J, Huber K, Glogar D, Gyöngyösi M.
    Thromb Haemost; 2008 Apr 12; 99(4):739-48. PubMed ID: 18392332
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug 12; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 20. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 12; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.